Wells Fargo & Company Akero Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 29,451 shares of AKRO stock, worth $831,696. This represents 0.0% of its overall portfolio holdings.
Number of Shares
29,451
Previous 20,126
46.33%
Holding current value
$831,696
Previous $508,000
35.83%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding AKRO
# of Institutions
168Shares Held
72.7MCall Options Held
178KPut Options Held
164K-
Janus Henderson Group PLC London, X06.88MShares$194 Million0.09% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$158 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.43MShares$153 Million2.13% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$148 Million3.88% of portfolio
-
Wellington Management Group LLP Boston, MA5.11MShares$144 Million0.02% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $1.31B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...